Charles River Laboratories Intl ( (CRL) ) has released its Q4 earnings. Here is a breakdown of the information Charles River Laboratories Intl presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles River Laboratories International, Inc. is a leading provider of products and services that support the drug discovery and development processes for pharmaceutical and biotechnology companies, government agencies, and academic institutions worldwide.
Charles River Laboratories reported its financial results for the fourth quarter and full-year 2024, showing a slight decrease in revenue compared to the previous year. Despite challenges, the company provided guidance for 2025, indicating plans for stock repurchases and a focus on cost-saving initiatives.
Key financial highlights include a fourth-quarter revenue of $1.00 billion and a full-year revenue of $4.05 billion, with a notable GAAP loss per share of $(4.22) for the fourth quarter. The non-GAAP earnings per share were $2.66 for the quarter and $10.32 for the year. The company experienced a significant goodwill impairment related to its Biologics Solutions unit, impacting its GAAP results. However, non-GAAP metrics showed an increase in net income and operating margins driven by the Manufacturing segment.
Looking ahead to 2025, Charles River Laboratories anticipates stable demand trends in the biopharmaceutical sector, with continued constraints from some clients but stable demand from biotechnology clients. The company plans to focus on executing revenue and cost-saving initiatives while repurchasing approximately $350 million in stock to enhance shareholder value.